Online inquiry

IVTScrip™ mRNA-Anti-LTB&TNFSF14, BG9924(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ3975MR)

This product GTTS-WQ3975MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets LTB&TNFSF14 gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_002341.2; NM_003807.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4050; 8740
UniProt ID Q06643; O43557
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-LTB&TNFSF14, BG9924(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ3975MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ13698MR IVTScrip™ mRNA-Anti-ERBB2, RC48(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA RC48
GTTS-WQ13583MR IVTScrip™ mRNA-Anti-IL13, QAX-576(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA QAX-576
GTTS-WQ13742MR IVTScrip™ mRNA-Anti-ANGPTL3, REGN 1500(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA REGN 1500
GTTS-WQ8513MR IVTScrip™ mRNA-Anti-B4GALNT1, Hu3F8(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA Hu3F8
GTTS-WQ7127MR IVTScrip™ mRNA-Anti-LHCGR, FE 999302(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA FE 999302
GTTS-WQ15755MR IVTScrip™ mRNA-Anti-CA9, WX-G250(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA WX-G250
GTTS-WQ11804MR IVTScrip™ mRNA-Anti-PDCD1, MK-3475(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MK-3475
GTTS-WQ9074MR IVTScrip™ mRNA-Anti-IGF1R, IMC-A12(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA IMC-A12
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW